KRAS and pancreatic neoplasm: Further study of EGFR-based therapy in patients’ subgroups, either selected by clinical parameters (e.g., with locally advanced disease) or defined by molecular subtype (e.g., KRAS wild-type pancreatic cancer) may be warranted, and an increased understanding of primary resistance, role of intracellular redundancy and cross-talk amongst signalling pathways, acquired resistance, interaction of EGFR inhibitors with chemotherapy and potential biomarkers of their activity are necessary for successful trial design in this disease group.